Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis Awarded $2.3M Grant to Build Out MDx Platform

NEW YORK (GenomeWeb) – The Flemish Government has awarded Biocartis a €1.7 million ($2.3 million) grant to build out the capabilities of the company's Idylla molecular diagnostics platform, Biocartis said today.

Biocartis said it will use the funding to further develop its hybrid multiplexing technology to detect and quantify multiple biomarker types on single Idylla tests. The company has developed oncology assays that can already detect tens of biomarkers of the same type.

"The hybrid multiplexing project will strengthen our competitive position in the oncology field and open new opportunities in other disease, such as infectious and genetic diseases," Biocartis CSO Geert Maertens said in a statement.

Earlier this month Biocartis and Abbott announced a collaboration to develop and commercialize companion diagnostic tests for use on the Idylla platform.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.